Affordable Access

deepdyve-link
Publisher Website

Risk of Cancers in Pediatric Inflammatory Bowel Diseases Patients: A Systematic Review and Meta-Analysis.

Authors
  • Komaki, Yuga1
  • Komaki, Fukiko1
  • Yamada, Akihiro2
  • Micic, Dejan3
  • Ido, Akio4
  • Sakuraba, Atsushi5
  • 1 Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, USA; Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan. , (Japan)
  • 2 Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, USA; Department of Internal Medicine, Toho University Sakura Medical Center, Chiba, Japan. , (Japan)
  • 3 Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, USA.
  • 4 Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan. , (Japan)
  • 5 Inflammatory Bowel Disease Center, The University of Chicago Medicine, Chicago, USA. Electronic address: [email protected]
Type
Published Article
Journal
The Journal of pediatrics
Publication Date
Sep 05, 2020
Identifiers
DOI: 10.1016/j.jpeds.2020.08.087
PMID: 32898579
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

We performed a systematic review and meta-analysis to evaluate the risk of the development of cancers in patients with pediatric-onset inflammatory bowel disease (IBD). A computerized literature search was performed. The primary outcome was the pooled incidence of cancer in studies reporting the risk as a standardized incidence ratio (SIR). The secondary outcomes were the pooled incidence rates of all cancers and site-specific cancers including colorectal cancer (CRC) and hematologic cancers. 66 studies reporting outcomes in 38,092 patients were included. The pooled SIR for cancer was 2.39 (P < .0001, 95% confidence interval (CI) = 2.00-2.86) in IBD. The pooled incidence rates for cancer in Crohn's disease (CD) and ulcerative colitis (UC) patients were 0.014 (95% CI = 0.0087-0.021) and 0.031 (95% CI = 0.018-0.052), respectively. The pooled incidence rate of CRC in CD and UC were 0.0075 (95% CI = 0.0049-0.011) and 0.020 (95% CI = 0.012-0.034), respectively. The pooled rates of hematologic cancers in CD and UC were 0.0061 (95% CI = 0.0040-0.0090) and 0.0045 (95% CI = 0.0026-0.0079), respectively. Cumulative meta-analyses showed a decreasing trend in the incidence of these cancers in both CD and UC. Patients with pediatric-onset IBD had an increased risk of cancers development compared with the general population, however, incidence appeared to be decreasing in recent years. Copyright © 2020 Elsevier Inc. All rights reserved.

Report this publication

Statistics

Seen <100 times